About ResMed

We develop innovative products to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing.

When ResMed was formed in 1989, our primary purpose was to commercialize a device for treating obstructive sleep apnea (OSA), a major subset of sleep-disordered breathing (SDB).

In 1981 Professor Colin Sullivan and colleagues at the University of Sydney developed the first continuous positive airway pressure (CPAP) device, the first successful, noninvasive treatment for obstructive sleep apnea (OSA). In 1989 ResMed was founded to commercialize a device for treating obstructive sleep apnea, a major subset of sleep-disordered breathing (SDB). Operations have grown dramatically in the past 25 years. Awareness about the dangers of untreated OSA has increased, and we have introduced new, highly innovative, product lines. ResMed now operates in 100 countries via direct offices and a network of distributors.

Since 1989, we have maintained our focus on SDB, while also expanding into the fields of respiratory medicine and cardiology. We help make quality care accessible for those with diseases such as chronic obstructive pulmonary disease and motor neuron disease.

View our full website at ResMed.com